Document is current
Any future updates will be listed below
-
Authors
Hartono, Muhamad
Baker, Andrew G.
Else, Thomas R.
Evtushenko, Alexander S.
Bohndiek, Sarah E.
Muñoz-Espín, Daniel
Fruk, Ljiljana
-
Funding
Funding for this research was provided by:
Gates Cambridge Scholarship
W. D. Armstrong Studentship
Cancer Research UK (C9545/A29580)
Cancer Research UK (C9545/A29580)
The Cambridge Trust
EPSRC (EP/R003599/1)
Cancer Research UK (CRUK) Cambridge Centre Early Detection Programme (RG86786)
CRUK Programme Foundation Award (C62187/A29760)
CRUK Early Detection Project Award (C62187/A26989)
Medical Research Council (MRC) New Investigator Research Grant (MR/R000530/1)
Darley/Sands Downing College Fellowship (G109261)
CRUK Early Detection Primer Award (EDDPMA-May23/100051)
EPSRC IRC grant (EPSRC IRC, EP/S009000/1)
- License Information
-
More Information
Article History
Received: 1 July 2024
Accepted: 11 November 2024
First Online: 27 November 2024
Declarations
:
: Ljiljana Fruk, Daniel Munoz Espin and Andrew G Baker are co-founders of Senesys Bio, a company improving the formulation of senolytics and declare competing interests. Other authors (MH, TRE, ASE and SEB) declare no competing interests.
